ClinicalTrials.gov
public full text
Public Domain
ACE2 Chewing Gum on SARS-CoV-2 Viral Load (COVID 19)
A randomized double-blind, placebo controlled clinical trial of the safety, tolerability, and antiviral activity of angiotensin-converting enzyme 2 (ACE2) chewing gum over a 3-day period in non-hospitalized subjects with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Severe Acute Respiratory Syndrome Coronavirus 2 Human Challenge Trials: Too Risky, Too Soon#717542
- Identification Of A Novel Coronavirus In Patients With Severe Acute Respiratory Syndrome#19588
- Newly Discovered Coronavirus As The Primary Cause Of Severe Acute Respiratory Syndrome#19577
- Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure#1124568
- Ezrin Peptide (HEP-1) for Treatment of Coronavirus Disease (COVID-19) Infection#628580
Record · ID 1337436
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive